Stock 1228 CANBRIDGE PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company CANbridge Pharmaceuticals Inc.

Equities

1228

KYG1821D1097

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:07 09/05/2024 pm IST 		5-day change 1st Jan Change
0.355 HKD -11.25% Intraday chart for CANbridge Pharmaceuticals Inc. -17.44% -64.14%
23/04 Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials MT
22/04 CANbridge Pharmaceuticals Inc. Announces Results of CAN008 Phase II Clinical Trial for the Treatment of Glioblastoma Multiforme CI

Business Summary

CANbridge Pharmaceuticals Inc is a China-based company mainly engaged in the research, development and commercialization of rare disease treatments. The Company's main businesses are the development, production, promotion and sales of medical products. The Company's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The Company's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The Company is also engaged in the development of gene therapy.

Number of employees: 100

Sales per Business

HKD in Million2022Weight2023Weight Delta
Medical Products
100.0 %
92 100.0 % 114 100.0 % +23.78%

Sales per region

HKD in Million2022Weight2023Weight Delta
China
54.3 %
37 39.9 % 62 54.3 % +68.60%
Other Regions
45.7 %
55 60.1 % 52 45.7 % -5.95%

Managers

Managers TitleAgeSince
James Xue CEO
 Chief Executive Officer 55 30/18/30
Glenn Hassan DFI
 Director of Finance/CFO 46 02/19/02
Gerald Cox CTO
 Chief Tech/Sci/R&D Officer - -
Minnie Ke CTO
 Chief Tech/Sci/R&D Officer - -
Qian Ma CMP
 Compliance Officer - 21/21/21
Pauline Li COO
 Chief Operating Officer - 08/22/08
Isabella Zhao IRC
 Investor Relations Contact - -
Zhang Wei PRN
 Corporate Officer/Principal - -
Hu Tianxin PRN
 Corporate Officer/Principal - -
Chris Chen HRO
 Human Resources Officer - -

Members of the board

Members of the board TitleAgeSince
Edward Hu BRD
 Director/Board Member 61 05/22/05
James Geraghty BRD
 Director/Board Member 69 18/18/18
Peng Kuan Chan BRD
 Director/Board Member 60 11/21/11
Lan Hu BRD
 Director/Board Member 55 16/22/16
James Xue CEO
 Chief Executive Officer 55 30/18/30
Richard Gregory BRD
 Director/Board Member 66 21/20/21
Lan Hu
53 -
Kan Chen BRD
 Director/Board Member 42 16/20/16

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 424,838,320 382,362,890 ( 90.00 %) 0 90.00 %

Shareholders

NameEquities%Valuation
Athos Capital Ltd.
12.40 %
52,665,590 12.40 % 2 M $
James Xue
9.833 %
41,775,430 9.833 % 2 M $
James Geraghty
0.1648 %
700,000 0.1648 % 27 279 $
RA Capital Management LP
0.000000 %
0 0.000000 % - $

Company contact information

CANbridge Pharmaceuticals Inc.

Suite 301, 3F, TImeloit No. 17 RongChuang Road

, Beijing

+86 10 8414 8018

http://www.canbridgepharma.com
address CANbridge Pharmaceuticals Inc.(1228)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Specialty & Advanced Pharmaceuticals

Sales per region

Ratings for CANbridge Pharmaceuticals Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.355 HKD
Average target price
12.3 HKD
Spread / Average Target
+3,364.79%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
CANBRIDGE PHARMACEUTICALS INC. Stock CANbridge Pharmaceuticals Inc.
-64.14% 21.74M
MERCK KGAA Stock Merck KGaA
+8.05% 72.03B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-11.95% 5.14B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+51.87% 4.6B
YUHAN CORPORATION Stock Yuhan Corporation
+3.92% 3.96B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-14.26% 2.5B
INDIVIOR PLC Stock Indivior PLC
+20.42% 2.43B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-23.94% 2.32B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+20.02% 2.18B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+3.66% 1.72B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 1228 Stock
  4. Company CANbridge Pharmaceuticals Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW